Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Type 2 Gaucher Disease”

108 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 108 results

Not applicableStudy completedNCT00351156
What this trial is testing

Study to Evaluate Blood Cell Lines From Patients With Gaucher Disease

Who this might be right for
Gaucher Disease
Amicus Therapeutics 50
Testing effectiveness (Phase 2)Study completedNCT01857934
What this trial is testing

Therapy for Children With Advanced Stage Neuroblastoma

Who this might be right for
Neuroblastoma
St. Jude Children's Research Hospital 153
Testing effectiveness (Phase 2)WithdrawnNCT03252171
What this trial is testing

CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients

Who this might be right for
GD2 Positive GliomaCAR-T Cell Immunotherapy
Fuda Cancer Hospital, Guangzhou
Early research (Phase 1)Looking for participantsNCT06641908
What this trial is testing

Anti-GD2 ADC M3554 in Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
EMD Serono Research & Development Institute, Inc. 65
Early research (Phase 1)Study completedNCT00877110
What this trial is testing

Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

Who this might be right for
NeuroblastomaBone Marrow, Sympathetic Nervous System
Memorial Sloan Kettering Cancer Center 71
Testing effectiveness (Phase 2)Study completedNCT00911560
What this trial is testing

Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma

Who this might be right for
Neuroblastoma
Memorial Sloan Kettering Cancer Center 374
Early research (Phase 1)Ended earlyNCT03170141
What this trial is testing

Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme

Who this might be right for
Glioblastoma Multiforme of BrainBrain Cancer
Shenzhen Geno-Immune Medical Institute 30
Not applicableUnknownNCT03812042
What this trial is testing

Screening of Lysosomal Storage Disorders Diseases in Minority Groups

Who this might be right for
Lysosomal Storage Diseases
Lysosomal and Rare Disorders Research and Treatment Center, Inc. 100,000
Testing effectiveness (Phase 2)Not Yet RecruitingNCT03356808
What this trial is testing

Antigen-specific T Cells Against Lung Cancer

Who this might be right for
Lung Cancer
Shenzhen Geno-Immune Medical Institute 20
Not applicableStudy completedNCT05687474
What this trial is testing

Baby Detect : Genomic Newborn Screening

Who this might be right for
Congenital Adrenal HyperplasiaFamilial Hyperinsulinemic Hypoglycemia 1Phosphoglucomutase 1 Deficiency+121 more
Centre Hospitalier Universitaire de Liege 6,824
Testing effectiveness (Phase 2)UnknownNCT05447494
What this trial is testing

Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease

Who this might be right for
Gaucher Disease, Type 1Gaucher Disease, Type 3
CANbridge (Suzhou) Bio-pharma Co., Ltd. 40
Testing effectiveness (Phase 2)Looking for participantsNCT06026657
What this trial is testing

Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8HER2-Negative Breast Carcinoma
Margaret Gatti-Mays 42
Testing effectiveness (Phase 2)Looking for participantsNCT07627698
What this trial is testing

Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma

Who this might be right for
Unresectable MelanomaMetastatic Cutaneous MelanomaMetastatic Uveal Melanoma
Beijing Biotech 36
Not applicableStudy completedNCT00244582
What this trial is testing

Convection-Enhanced Delivery of Glucocerebrosidase to Treat Type 2 Gaucher Disease

Who this might be right for
Type 2 Gaucher Disease
National Institute of Neurological Disorders and Stroke (NINDS) 1
Early research (Phase 1)Looking for participantsNCT04099797
What this trial is testing

C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)

Who this might be right for
Diffuse Intrinsic Pontine GliomaHigh Grade GliomaEmbryonal Tumor+1 more
Baylor College of Medicine 56
Testing effectiveness (Phase 2)Active Not RecruitingNCT04411654
What this trial is testing

Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)

Who this might be right for
Gaucher Disease, Type 2
Prevail Therapeutics 7
Testing effectiveness (Phase 2)Ended earlyNCT05437328
What this trial is testing

GD2/CD56 Bi-specific CAR-T Cell Therapy

Who this might be right for
Malignant Disease
Shenzhen Geno-Immune Medical Institute 60
Early research (Phase 1)Study completedNCT02107963
What this trial is testing

A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors

Who this might be right for
SarcomaOsteosarcomaNeuroblastoma+1 more
National Cancer Institute (NCI) 15
Testing effectiveness (Phase 2)Looking for participantsNCT06450041
What this trial is testing

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Who this might be right for
Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium 62
Large-scale testing (Phase 3)Looking for participantsNCT06669013
What this trial is testing

Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas

Who this might be right for
Bone SarcomaEmbryonal RhabdomyosarcomaAlveolar Rhabdomyosarcoma
N.N. Petrov National Medical Research Center of Oncology 40
Next Page